(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 September 2023 (28.09.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/180171 A1

(51) International Patent Classification:
A61P 7/00 (2006.01) *A61K 31/5415* (2006.01)

(21) International Application Number:
PCT/EP2023/056759

(22) International Filing Date:
16 March 2023 (16.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2204185.9 24 March 2022 (24.03.2022) GB

(71) Applicant: **WISTA LABORATORIES LTD** [SG/SG]; 25 Bukit Batok Crescent, The Elitist #06-13, Singapore 658066 (SG).

(72) Inventor; and

(71) Applicant *(for MG only)*: **HARRINGTON, Charles Robert** [GB/GB]; WisTa Laboratories Ltd., Institute of Medical Sciences, University of Aberdeen, Aberdeenshire AB25 2ZD (GB).

(72) Inventors: **ARASTOO, Mohammad**; Institute of Medical Sciences, University of Aberdeen, Aberdeenshire AB25 2ZD (GB). **MAZANETZ, Michael Philip**; NovaData Solutions Ltd., 15 Monreith Road, Glasgow G43 2NX (GB). **SHIELLS, Helen**; TauRx Therapeutics Ltd., 395 King Street, Aberdeen Aberdeenshire AB24 5RP (GB). **STOREY, John Mervyn David**; Department of Chemistry, Meston Walk, Old Aberdeen Aberdeenshire AB24 3UE (GB). **WISCHIK, Claude Michel**; TauRx Therapeutics Ltd., 395 King Street, Aberdeen Aberdeenshire AB24 5RP (GB).


(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) **Title:** METHYLENE BLUE CONTAINING COMPOUNDS FOR THE TREATMENT OF METHAEMOGLOBINAEMIA



(57) **Abstract:** The invention provides novel methods of treating methaemoglobinaemia orally in a subject, which methods comprise orally administering to said subject a methylthioninium ("MT") containing salt of the following formula: wherein each of HnA and HnB (where present) are protic acids which may be the same or different, and wherein p = 1 or 2; q = 0 or 1; n = 1 or 2; (p + q) × n = 2, or a hydrate or solvate thereof. The administration should provide a total daily oral dose of 4 mg to 60 mg of MT to the subject per day.

WO 2023/180171 A1